Acadia Pharmaceuticals Inc [ACAD] stock prices are up 2.31% to $15.93 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ACAD shares have gain 5.22% over the last week, with a monthly amount drifted -12.42%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Acadia Pharmaceuticals Inc [NASDAQ: ACAD] stock has seen the most recent analyst activity on August 07, 2024, when Morgan Stanley downgraded its rating to a Equal-Weight and also revised its price target to $20 from $28. Previously, BMO Capital Markets started tracking the stock with Outperform rating on June 27, 2024, and set its price target to $31. On March 12, 2024, Needham reiterated its Buy rating and revised its price target to $32 on the stock. Mizuho downgraded its rating to a Neutral and decreased its price target to $25 on March 12, 2024. Robert W. Baird initiated its recommendation with a Outperform and recommended $40 as its price target on January 30, 2024. Needham upgraded its rating to Buy for this stock on January 24, 2024, but kept the price target unchanged to $37. In a note dated December 19, 2023, Morgan Stanley upgraded an Overweight rating on this stock and boosted its target price from $31 to $40.
The stock price of Acadia Pharmaceuticals Inc [ACAD] has been fluctuating between $14.55 and $32.59 over the past year. Currently, Wall Street analysts expect the stock to reach $26.57 within the next 12 months. Acadia Pharmaceuticals Inc [NASDAQ: ACAD] shares were valued at $15.93 at the most recent close of the market. An investor can expect a potential return of 66.79% based on the average ACAD price forecast.
Analyzing the ACAD fundamentals
The Acadia Pharmaceuticals Inc [NASDAQ:ACAD] reported sales of 890.53M for trailing twelve months, representing a surge of 46.44%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at 0.03%, Pretax Profit Margin comes in at 0.05%, and Net Profit Margin reading is 0.03%. To continue investigating profitability, this company’s Return on Assets is posted at 0.03, Equity is 0.07 and Total Capital is 0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.74 points at the first support level, and at 15.54 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.05, and for the 2nd resistance point, it is at 16.16.
Ratios To Look Out For
It’s worth pointing out that Acadia Pharmaceuticals Inc [NASDAQ:ACAD]’s Current Ratio is 2.16. As well, the Quick Ratio is 1.95, while the Cash Ratio is 0.52. Considering the valuation of this stock, the price to sales ratio is 2.97, the price to book ratio is 5.11 and price to earnings (TTM) ratio is 89.24.
Transactions by insiders
Recent insider trading involved Schneyer Mark C., EVP, CHIEF FINANCIAL OFFICER, that happened on Aug 19 ’24 when 9733.0 shares were sold. EVP, COO, HEAD OF COMMERCIAL, Teehan Brendan completed a deal on Aug 19 ’24 to sell 9534.0 shares. Meanwhile, CEO DAVIS STEPHEN sold 31747.0 shares on Aug 19 ’24.
